Enhanced omega-3 formulations

Patent metadata

Field	Value
Publication number	US-2016175366-A1
Application number	US-201514965433-A
Country	US
Kind code	A1
Filing date	Dec 10, 2015
Priority date	Dec 19, 2014
Publication date	Jun 23, 2016
Grant date	—

Abstract

The present invention relates to enhanced omega-3 formulations, and in particular to formulations comprising a phospholipid fraction and a triglyceride fraction in combinations with agents that provide a formulation with improved viscosity and dispersion characteristics.

First claim

1 . A lipid formulation comprising:
about 25 to 55% w/w of a first lipid fraction comprising from about 50% to 100% w/w phospholipids derived from a marine source; about 40% to 70% w/w of a second lipid fraction comprising from about 70% to 100% triglycerides; and one or more additives selected from the group consisting of about 1% to 8% of an alcohol and about 1% to 20% of a surfactant and combinations thereof.

2 . The lipid formulation of claim 1 , wherein said first and second lipid fractions are extracted from different source materials.

3 . The lipid formulation of claim 1 , wherein said first and second lipid fractions are fractions that are separately extracted from the same source material.

4 . The lipid formulation of claim 1 , wherein said first lipid fraction is extracted from a marine source selected from the group consisting of krill, squid and herring.

5 . The lipid formulation of claim 4 , wherein said first lipid fraction is extracted from a krill source material.

6 . The lipid formulation of claim 1 , wherein said first lipid fraction is a krill lipid fraction comprising from about 50% to 100% phospholipids w/w, said phospholipids being further characterized in having a combined EPA and DHA content of from about 25% to 40% w/w of the krill lipid fraction.

7 . The lipid formulation of claim 1 , wherein said first lipid fraction is a krill lipid fraction comprising a mixture of phospholipid compounds of formula (I):

wherein:
R 1 and R 2 are each independently selected from a fatty acid moiety of formula —COC n H m , a fatty acid moiety of formula —CH 2 C n H m , and —H;
R 1 and R 2 include omega-3 fatty acid moieties, such that at least 30% by weight of the phospholipid compounds is composed of omega-3 fatty acid moieties;
at least 90% by weight of total omega-3 fatty acid moieties are at position R 2 ;
R 1 and R 2 are not both —H in a phospholipid compound, and R 1 or R 2 is —H in less than 3% by weight of the compounds of formula (I);
R 3 is selected from —H, a choline moiety, an ethanolamine moiety, a N-acetylethanolamine moiety, an inositol moiety, and a serine moiety; and
R 3 is a choline moiety in at least 85% by number of the compounds of formula (I).

and wherein the krill phospholipid fraction also has one or more of the following properties:
(a) at least 50% by weight of the krill phospholipid fraction consists of phospholipid compounds of formula (I);
(b) the weight ratio of C16:0/C14:0 fatty acid moieties in the krill phospholipid fraction is between 10:1 and 18:1 and/or the weight ratio of C18:4 n-3/C18:3 n-3 fatty acid moieties is between 1:1 and 3:2;
(c) the krill phospholipid fraction includes less than 300 μg astaxanthins per gram of phospholipid;
(d) the krill phospholipid fraction comprises less than 0.01% by weight trimethylamine N-oxide;
(e) the krill phospholipid fraction comprises less than 0.01% by weight homarine;
(f) the krill phospholipid fraction includes less than 5% by weight water;
(g) the krill phospholipid fraction has less than about 0.03% by weight PUFA polymers
(h) the krill phospholipid fraction includes both phospholipids where R 1 is a fatty acid moiety of formula —COC n H m and phospholipids where R 1 is a fatty acid moiety of formula —CH 2 C n H m ;
(i) the krill phospholipid fraction includes both phospholipids where R 1 is an omega-3 fatty acid moiety and phospholipids where R 2 is an omega-3 fatty acid moiety;
(j) the krill phospholipid fraction includes less than 5% by weight sphingomyelin;
(k) the krill phospholipid fraction is free from chloroform and hexane; and/or
(l) less than 0.9% by weight of phospholipids in the composition is formed of compounds where R 1 or R 2 is —H, or more than 1.1% by weight of phospholipids in the composition is formed of compounds where R 1 or R 2 is —H.

8 . The lipid formulation of claim 1 , wherein said second lipid fraction is extracted from a marine source.

9 . The lipid formulation of claim 8 , wherein said marine source is selected from the group consisting of krill, squid, fish and marine algae.

10 . The lipid formulation of claim 1 , wherein said second lipid fraction is a triglyceride omega-3 concentrate.

11 . The lipid formulation of claim 10 , wherein said triglyceride omega-3 concentrate is a fish oil concentrate.

12 . The lipid formulation of claim 10 , wherein said triglyceride omega-3 concentrate is characterized in comprising a combined content of EPA and DHA of from about 45% to 80% w/w of said triglyceride omega-3 concentrate.

13 . The lipid formulation of claim 10 , wherein said triglyceride omega-3 concentrate is characterized in comprising a combined content of EPA and DHA of from about 60% to 80% w/w of said triglyceride omega-3 concentrate.

14 . The lipid formulation of claim 1 , wherein said lipid formulation comprises a total EPA and DHA content of from about 350 mg to 700 mg per gram of said formulation.

15 . The lipid formulation of claim 1 , wherein said lipid formulation comprises a total EPA and DHA content of from about 400 mg to 600 mg per gram of said formulation.

16 . The lipid formulation of claim 1 , wherein said lipid formulation comprises a total EPA and DHA content of from about 425 mg to 575 mg per gram of said formulation.

17 . The lipid formulation of claim 1 , wherein said alcohol is a food grade alcohol.

18 . The lipid formulation of claim 17 , wherein said food grade ethanol is ethanol.

19 . The lipid formulation of claim 1 , wherein said lipid formulation comprises from about 0.5% to 4% w/w of said alcohol.

20 . The lipid formulation of claim 1 , wherein said lipid formulation comprises from about 1% to 3% w/w of said alcohol.

21 . The lipid formulation of claim 1 , further comprising from about 1% to 20% of a surfactant.

22 . The lipid formulation of claim 21 further comprising from about 5% to 15% of a surfactant.

23 . The lipid formulation of claim 1 , wherein said surfactant is selected from the group consisting of a polysorbate and a sorbitan ester.

24 . The lipid formulation of claim 23 , wherein said polysorbate is selected from the group consisting of Polysorbate 20 (Polyoxyethylene (20) sorbitan monolaurate), Polysorbate 40 (Polyoxyethylene (20) sorbitan monopalmitate), Polysorbate 60 (Polyoxyethylene (20) sorbitan monostearate), and Polysorbate 80 (Polyoxyethylene (20) sorbitan monooleate).

25 . The lipid formulation of claim 23 , wherein said sorbitan ester is selected from the group consisting of Sorbitan monolaurate, Sorbitan monopalmitate, Sorbitan monostearate, Sorbitan monooleate, Sorbitan sesquioleate, Sorbitan trioleate and Sorbitan isostearate.

26 . The lipid formulation of claim 1 , wherein said lipid formulation has a viscosity of from about 20 to 200 mPas at 30° C.

27 . The lipid formulation of claim 1 , wherein said lipid formulation has a viscosity of from about 50 to 150 mPas at 30° C.

28 . The lipid formulation of any of claim 1 , wherein said formulation is provided in a formulation selected from the group consisting of a capsule, a tablet, a liquid, a powder, an emulsion, a dietary supplement, a nutritional supplement, a beverage and a functional food.

29 . A method for

Assignees

• Aker Biomarine Antarctic As

Inventors

• Hupfeld Stefan

Classifications

• A61K31/232

  having three or more double bonds, e.g. etretinate · CPC title

• A61K31/661

  Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos} · CPC title

• A61K35/612 Primary

  Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles · CPC title

• C11B1/10

  by extracting · CPC title

• A23D9/013

  Other fatty acid esters, e.g. phosphatides · CPC title